Proteasome-Ubiquitin System Dysfunction Validation in Parkinson's Disease

Pathway Diagram

Experiment Overview

Experiment ID: PUMPS-PD-001 Hypothesis: Proteasome-Ubiquitin System Dysfunction Hypothesis in Parkinson's Disease Primary Objective: Validate that UPS dysfunction is a primary driver of alpha-synuclein aggregation and dopaminergic neurodegeneration in PD Study Type: Multi-phase translational study (preclinical + clinical)

Study Design

Phase 1: In Vitro Validation (Months 1-6)

1.1 Proteasome Activity Assays

Objective: Measure baseline proteasome activity in PD patient-derived cells

Models:

• iPSC-derived dopaminergic neurons from PD patients (LRRK2 G2019S,GBA, idiopathic)
• Age-matched healthy controls
• Isogenic controls with gene corrections

• 20S proteasome chymotrypsin-like activity (fluorescent substrate)
• 20S proteasome trypsin-like activity
• 20S proteasome caspase-like activity
• 26S proteasome ATP-dependent activity
• Ubiquitin conjugate accumulation (Western blot)
• Alpha-synuclein turnover rates (pulse-chase)

Pathway Diagram

Experiment Overview

Experiment ID: PUMPS-PD-001 Hypothesis: Proteasome-Ubiquitin System Dysfunction Hypothesis in Parkinson's Disease Primary Objective: Validate that UPS dysfunction is a primary driver of alpha-synuclein aggregation and dopaminergic neurodegeneration in PD Study Type: Multi-phase translational study (preclinical + clinical)

Study Design

Phase 1: In Vitro Validation (Months 1-6)

1.1 Proteasome Activity Assays

Objective: Measure baseline proteasome activity in PD patient-derived cells

Models:

• iPSC-derived dopaminergic neurons from PD patients (LRRK2 G2019S,GBA, idiopathic)
• Age-matched healthy controls
• Isogenic controls with gene corrections

• 20S proteasome chymotrypsin-like activity (fluorescent substrate)
• 20S proteasome trypsin-like activity
• 20S proteasome caspase-like activity
• 26S proteasome ATP-dependent activity
• Ubiquitin conjugate accumulation (Western blot)
• Alpha-synuclein turnover rates (pulse-chase)

1.2 Alpha-Synuclein Clearance Kinetics

Objective: Determine if UPS impairment specifically affects alpha-synuclein degradation

Methods:

• Proteasome inhibition (MG132, bortezomib) dose-response
• Alpha-synuclein half-life measurement with cycloheximide chase
• Ubiquitination status of alpha-synuclein
• Interaction with autophagy compensation

Phase 2: Preclinical Validation (Months 6-12)

2.1 Animal Model Studies

Objective: Validate UPS dysfunction as upstream driver in vivo

Models:

• A53T alpha-synuclein transgenic mice
• UCHL1 mutant mice (UCHL1^S18Y knock-in)
• Proteasome hypomorphic mice (PSMA3^D7/D7)
• Combination models

• Proteasome activators (natural compounds: EGCG, ursolic acid)
• Deubiquitinase modulators (UDCA, gene therapy)
• Proteasome subunit overexpression

• Behavioral assessment (rotarod, cylinder test, gait analysis)
• Proteasome activity in substantia nigra
• Alpha-synuclein aggregation (IHC, Western blot)
• Dopaminergic neuron survival (TH+ neuron counts)
• Motor performance correlation

2.2 Mechanism Validation

Objective: Confirm feed-forward loops between UPS dysfunction and alpha-synuclein

Measurements:

• Proteasome subunit composition changes
• Ubiquitin cascade alterations
• Autophagy compensation markers
• Mitochondrial function correlation

Phase 3: Clinical Translation (Months 12-24)

3.1 Biomarker Validation

Objective: Validate peripheral proteasome activity as PD biomarker

Cohorts:

• Early PD (n=100)
• Moderate PD (n=100)
• Advanced PD (n=100)
• Healthy controls (n=100)
• Other neurodegenerative disease controls (n=50 each: AD, ALS)

• Peripheral blood mononuclear cells (PBMCs)
• CSF proteasome activity
• Skin fibroblasts
• Exosomes

• PBMC proteasome activity correlation with disease severity
• CSF proteasome activity and ubiquitin levels
• Predictive value for progression
• Specificity for PD vs. other diseases

3.2 Therapeutic Target Engagement

Objective: Demonstrate target engagement of proteasome-enhancing interventions

Intervention: Dietary supplementation with proteasome-enhancing compounds

Endpoints:

• Peripheral proteasome activity change
• Biomarker correlation with motor outcomes
• Safety profile

Primary Endpoints

| Endpoint | Method | Expected Result |
|----------|--------|-----------------|
| Proteasome activity | Fluorometric assay | Reduced in PD vs. controls |
| Alpha-synuclein half-life | Pulse-chase | Prolonged in PD neurons |
| Ubiquitin conjugates | Western blot | Increased in PD |
| Dopaminergic neuron survival | TH+ IHC | Correlation with proteasome activity |

Secondary Endpoints

• Autophagy compensation markers (LC3, p62)
• Mitochondrial function (OCR, membrane potential)
• Neuroinflammation markers (IL-6, TNF-α in CSF)
• Motor function correlation (UPDRS, MoCA)

Statistical Analysis

• Primary: t-test/Wilcoxon for proteasome activity (PD vs. controls)
• Correlation: Spearman correlation with UPDRS scores
• Survival analysis: Cox regression for progression
• Power: 80% power to detect 30% reduction at α=0.05

Safety Considerations

• Monitor for protein overload toxicity with proteasome activators
• Assess hepatic and renal function
• Document any unexpected behavioral changes

Budget Estimate

| Category | Cost (USD) |
|----------|------------|
| Personnel | $300,000 |
| iPSC lines | $50,000 |
| Reagents | $80,000 |
| Animal work | $150,000 |
| Clinical sample collection | $100,000 |
| Total | $680,000 |

Timeline

• Month 1-6: In vitro experiments
• Month 6-12: Preclinical animal studies
• Month 12-18: Clinical biomarker validation
• Month 18-24: Therapeutic pilot study
• Month 24: Final analysis and publication

Success Criteria

Cross-References

• [Parkinson's Disease](/diseases/parkinsons-disease) — Primary disease target
• [Alpha-Synuclein Pathway](/mechanisms/alpha-synuclein-pathology) — Aggregation substrate
• [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system) — UPS mechanism
• [LRRK2 Gene](/genes/lrrk2) — LRRK2 G2019S mutation
• [GBA Gene](/genes/gba) — GBA mutations, lysosomal dysfunction
• [Substantia Nigra](/brain-regions/substantia-nigra) — Affected brain region
• [Dopaminergic Neurons](/cell-types/mesencephalic-dopaminergic-neurons) — Target neurons
• [Proteasome Activators](/therapeutics/proteasome-activators) — EGCG, ursolic acid
• [Autophagy Enhancement](/therapeutics/autophagy-enhancement-therapy) — Compensatory clearance
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-parkinsons) — Convergent pathway
• [Neuroinflammation](/mechanisms/neuroinflammation-parkinsons) — Inflammatory cascade
• [iPSC Models](/cell-types/ipsc-derived-dopaminergic-neurons) — Disease modeling
• [Biomarker Development](/mechanisms/biomarker-development-neurodegeneration) — Peripheral markers

See Also

• [Sodium Oligomannate (GV-971) for Alzheimer's Disease](/wiki/therapeutics-sodium-oligomannate-gv971) — regulates
• [Ubiquitin](/wiki/proteins-ubiquitin) — binds_to